WO2017108010A1 - 一种伏立康唑中间体及伏立康唑的合成方法 - Google Patents
一种伏立康唑中间体及伏立康唑的合成方法 Download PDFInfo
- Publication number
- WO2017108010A1 WO2017108010A1 PCT/CN2017/071250 CN2017071250W WO2017108010A1 WO 2017108010 A1 WO2017108010 A1 WO 2017108010A1 CN 2017071250 W CN2017071250 W CN 2017071250W WO 2017108010 A1 WO2017108010 A1 WO 2017108010A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- organic solvent
- reaction
- aprotic organic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
Definitions
- the invention relates to a method for synthesizing an important intermediate condensate hydrochloride of voriconazole and voriconazole.
- Voriconazole (VRC, UK109496) is a new antifungal drug synthesized by Pfizer Inc. on the basis of fluconazole. It is mainly used for patients with progressive and fatal immune damage. Because voriconazole has a broad spectrum of antifungal activity, strong antibacterial effect, good safety, and the demand for antifungal drugs in the domestic market is growing rapidly, the market prospect is huge.
- Voriconazole its chemical name is (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-tri Zin-1-yl)-2-butanol, the structural formula is as shown in formula I:
- the voriconazole condensate is an important intermediate with the chemical name: (2R, 3S/2S, 3R)-3-(6-chloro-5-fluoropyrimidin-4-yl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl )-2-butanol, the structural formula is as shown in formula II:
- the main synthesis method of the intermediate formula II is as shown in the reaction formula 1, using 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazole) having the structural formula as shown in III.
- -1-yl)ethanone and 4-(1-bromoethyl)-5-fluoro-6-chloropyrimidine of the formula IV as in the presence of metallic zinc, iodine or Lewis acid and an aprotic organic solvent
- the reaction is carried out in the presence or absence of lead.
- the mechanism is that the zinc powder is first reacted with a compound of formula IV to form an organozinc reagent which is then reacted with a compound of formula III.
- the compounds of formula III and IV can be prepared using commercially available starting materials or by methods disclosed in the prior art.
- impurity A 3-(6-(1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl)-5-fluoropyrimidin-4-yl)-2-(2,4-di Fluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol, the structural formula is as shown in formula V:
- the invention provides a novel synthesis method of a voriconazole intermediate condensate of the formula II or an acid addition salt thereof, which can effectively reduce the formation of the impurity A by controlling the feeding mode.
- the present invention provides a novel method for synthesizing a voriconazole intermediate condensate of formula II or an acid addition salt thereof, which comprises reacting a compound of formula III with a compound of formula IV in the presence of zinc and Lewis acid, and The reaction is carried out in an aprotic organic solvent at a certain reaction temperature in the absence of an activator. As shown in the reaction formula 1, the method comprises the following steps:
- an activator is present therein.
- the activator comprises iodine, bromine, dibromohydantoin or 1,2-dibromoethane, preferably iodine and bromine.
- the activator is used in a weight ratio of the compound to the formula III of from 0.05 to 2.0:1, preferably from 0.1 to 0.2:1.
- the molar ratio of zinc, compound of formula IV to compound III is from 1-10:0.5 to 2.5:1, preferably from 1.2 to 1.5:1.2 to 1.5:1.
- the temperature of the reaction is from 0 to 50 ° C, preferably from 10 to 25 ° C.
- the Lewis acid used in the reaction includes a chloride salt, a bromide salt, an iodide salt, an alumina trioxide, a titanium isopropoxide, a titanium triisopropoxide, a boron trifluoride or a boric acid.
- the trimethyl ester is preferably zinc chloride.
- the step (a1) is the same as the aprotic organic solvent used in the step (b1) or the step (a2) and the step (b2).
- the aprotic organic solvent comprises a C 2 - C 10 aprotic organic solvent, preferably a substituted or unsubstituted ether solvent, an alkane solvent or an aromatic hydrocarbon solvent, more preferably tetrahydrofuran.
- the invention also provides a method for synthesizing voriconazole, which comprises further reducing the intermediate condensate prepared by the synthesis method according to claim 1 or the acid addition salt thereof to obtain the formula VI, and then dissolving the voriconazole,
- the specific synthetic route is as follows:
- the reaction condition is mild and controllable by adjusting the feeding mode of the reaction for generating the voriconazole intermediate condensate;
- the impurity A in the above reaction can be controlled within 0.74%, thereby reducing the formation of the impurity A;
- THF (160 g) and compound III (20 g) were added to the flask under nitrogen atmosphere at 20 ⁇ 5 ° C, stirred until clear, and ZnCl 2 (13.6 g) and zinc powder (8.6 g) were added to form a suspension.
- a solution of iodine (2.0 g) and compound IV (30 g) in THF (160 g) was added dropwise to the suspension. After the end of the reaction for 3 hours, the reaction was terminated by dropwise addition of a mixed solution of acetic acid (5.6 g) and water (160 mL).
- the reaction mixture was concentrated under reduced pressure, and dichloromethane (208 g), water (100 mL) and acetic acid (5.8 g)
- dichloromethane 208 g
- water 100 mL
- acetic acid 5.8 g
- the aqueous layer was washed once with dichloromethane (110 g) and the organic phases were combined.
- the organic phase was washed with a sodium hydrogencarbonate aqueous solution, dried and concentrated, and then hydrochloric acid was added dropwise to form a salt.
- the reaction mixture was concentrated under reduced pressure, dichloromethane (40 g) and water (24 g) were evaporated. The mixture was partitioned and the aqueous layer was extracted twice with dichloromethane (40 g). Water (30 g) was added to the organic phase, and the pH was adjusted to 9 to 11 by adding a liquid alkali to separate the layers. The organic phase was dried over anhydrous magnesium sulfate, filtered and evaporated. Then, isopropanol (19 g) was added to the obtained concentrate, and the mixture was heated to reflux for 20 minutes with stirring, and then cooled to 20 to 30 ° C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
Abstract
Description
Claims (10)
- 一种如式II所示的伏立康唑的重要中间体缩合物或其酸加成盐的合成方法,包括将式III所示的化合物与式IV所示的化合物在锌和Lewis酸存在下,及有或无活化剂存在下,在一定的反应温度下,在非质子性有机溶剂中进行反应,如反应式1所示,其特征在于,该方法包括如下步骤:(a1)将化合物式III、锌和Lewis酸与非质子性有机溶剂混合,形成悬浮液;(b1)将化合物式IV与非质子性有机溶剂混合,其中任选地有活化剂存在,形成溶液;(c1)将步骤(b1)形成的溶液缓慢加入到步骤(a1)形成的悬浮液中进行反应,得到式II所示的中间体缩合物;(d1)任选地将式II化合物转化为其酸加成盐;或者(a2)将化合物式III、锌和Lewis酸与非质子性有机溶剂混合,形成悬浮液;(b2)将化合物式IV与非质子性有机溶剂混合,形成溶液;(c2)将步骤(b2)形成的溶液缓慢加入到步骤(a2)形成的悬浮液中进行反应,其中任选地有活化剂存在,得到式II所示的中间体缩合物;(d2)任选地将式II化合物转化为其酸加成盐;或者(a3)将化合物式III、化合物式IV和Lewis酸与非质子性有机溶剂混合,形成悬浮液;(b3)将锌加入到上述悬浮液中,其中任选地有活化剂存在,得到式II所示的中间体缩合物;(c3)任选地将式II化合物转化为其酸加成盐;
- 根据权利要求1所述的合成方法,其特征在于:其中有活化剂存在。
- 根据权利要求2所述的合成方法,其特征在于:所述活化剂包括碘、溴、二溴海因或1,2-二溴乙烷,优选碘和溴。
- 根据权利要求2或3所述的合成方法,其特征在于:所述活化剂的使用量与化合物式III的重量比为0.05-2.0:1,优选0.1-0.2:1。
- 根据权利要求1-3任一项所述的合成方法,其特征在于:锌、化合物式IV的使用量与化合物式Ⅲ摩尔比为1-10:0.5-2.5:1,优选1.2-1.5:1.1-1.5:1。
- 根据权利要求1-3任一项所述的合成方法,其特征在于:所述反应的温度为0-50℃,优选10-25℃。
- 根据权利要求1-3任一项所述的合成方法,其特征在于:反应中使用的Lewis酸包括氯化盐、溴化盐、碘化盐、三氧化二铝、异丙氧钛、三异丙氧氯化钛、三氟化硼或硼酸三甲酯,优选为氯化锌。
- 根据权利要求1-3任一项所述的合成方法,其特征在于:步骤(a1)与步骤(b1)或步骤(a2)与步骤(b2)所用的非质子性有机溶剂相同。
- 根据权利要求1-3任一项所述的合成方法,其特征在于:所述非质子性有机溶剂为C2-C10的非质子性有机溶剂,优选取代或未取代的醚类溶剂、烷烃溶剂或芳香烃溶剂,更优选四氢呋喃。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES17732011T ES2822081T3 (es) | 2015-12-23 | 2017-01-16 | Intermediario de voriconazol y método de síntesis de voriconazol |
US16/064,003 US10633368B2 (en) | 2015-12-23 | 2017-01-16 | Voriconazole intermediate and voriconazole synthesis method |
EP17732011.6A EP3395813B1 (en) | 2015-12-23 | 2017-01-16 | Voriconazole intermediate and voriconazole synthesis method |
JP2018532219A JP6681989B2 (ja) | 2015-12-23 | 2017-01-16 | ボリコナゾール中間体及びボリコナゾールの合成方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510984590.0 | 2015-12-23 | ||
CN201510984590 | 2015-12-23 | ||
CN201610031465.2 | 2016-01-18 | ||
CN201610031465.2A CN105503834B (zh) | 2015-12-23 | 2016-01-18 | 一种伏立康唑中间体的合成方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017108010A1 true WO2017108010A1 (zh) | 2017-06-29 |
Family
ID=55712203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/071250 WO2017108010A1 (zh) | 2015-12-23 | 2017-01-16 | 一种伏立康唑中间体及伏立康唑的合成方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10633368B2 (zh) |
EP (1) | EP3395813B1 (zh) |
JP (1) | JP6681989B2 (zh) |
CN (1) | CN105503834B (zh) |
ES (1) | ES2822081T3 (zh) |
WO (1) | WO2017108010A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105503834B (zh) * | 2015-12-23 | 2021-03-05 | 浙江华海药业股份有限公司 | 一种伏立康唑中间体的合成方法 |
CN106432198B (zh) | 2016-09-08 | 2022-10-21 | 浙江华海药业股份有限公司 | 一种制备伏立康唑拆分中间体的方法 |
CN109705102A (zh) * | 2019-02-19 | 2019-05-03 | 浙江华海立诚药业有限公司 | 伏立康唑及其中间体的制备方法 |
CN110724130A (zh) * | 2019-11-29 | 2020-01-24 | 怀化学院 | 伏立康唑及其中间体的合成方法 |
CN112645935A (zh) * | 2020-12-15 | 2021-04-13 | 植恩生物技术股份有限公司 | 伏立康唑关键中间体的制备方法 |
CN116106434A (zh) * | 2022-03-17 | 2023-05-12 | 南京易亨制药有限公司 | 高效检测4-氯-6-乙基-5-氟嘧啶中有关物质的方法 |
CN115724829A (zh) * | 2022-12-23 | 2023-03-03 | 天津力生制药股份有限公司 | 一种分离真菌药物中间体杂质的液相色谱制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1195346A (zh) * | 1995-08-05 | 1998-10-07 | 辉瑞研究开发公司 | 通过有机金属化合物对酮及其中间体的加成合成三唑化合物 |
CN102344441A (zh) * | 2010-07-25 | 2012-02-08 | 浙江华海药业股份有限公司 | 一种制备伏立康唑中间体的工艺改进方法 |
CN105503834A (zh) * | 2015-12-23 | 2016-04-20 | 浙江华海药业股份有限公司 | 一种伏立康唑中间体的合成方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1195340A (en) * | 1916-08-22 | Adjustable seat | ||
WO2009084029A2 (en) * | 2007-12-03 | 2009-07-09 | Neuland Laboratories Ltd | Improved process for the preparation of (2r,3s)-2-(2,4- difluqrophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol |
AU2012221788A1 (en) * | 2011-02-21 | 2013-09-05 | Sun Pharmaceutical Industries Limited | An improved process for the preparation of voriconazole and intermediates thereof |
-
2016
- 2016-01-18 CN CN201610031465.2A patent/CN105503834B/zh active Active
-
2017
- 2017-01-16 JP JP2018532219A patent/JP6681989B2/ja active Active
- 2017-01-16 WO PCT/CN2017/071250 patent/WO2017108010A1/zh active Application Filing
- 2017-01-16 ES ES17732011T patent/ES2822081T3/es active Active
- 2017-01-16 US US16/064,003 patent/US10633368B2/en active Active
- 2017-01-16 EP EP17732011.6A patent/EP3395813B1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1195346A (zh) * | 1995-08-05 | 1998-10-07 | 辉瑞研究开发公司 | 通过有机金属化合物对酮及其中间体的加成合成三唑化合物 |
CN102344441A (zh) * | 2010-07-25 | 2012-02-08 | 浙江华海药业股份有限公司 | 一种制备伏立康唑中间体的工艺改进方法 |
CN105503834A (zh) * | 2015-12-23 | 2016-04-20 | 浙江华海药业股份有限公司 | 一种伏立康唑中间体的合成方法 |
Non-Patent Citations (1)
Title |
---|
TONG, LIHUA ET AL.: "Synthesis of a Novel Antifungal Drug Voriconazole", CENTRAL SOUTH PHARMACY, vol. 8, no. 4, 30 April 2010 (2010-04-30), pages 280 - 282, XP009162282 * |
Also Published As
Publication number | Publication date |
---|---|
EP3395813B1 (en) | 2020-08-26 |
EP3395813A4 (en) | 2019-06-05 |
CN105503834A (zh) | 2016-04-20 |
JP2019505499A (ja) | 2019-02-28 |
CN105503834B (zh) | 2021-03-05 |
JP6681989B2 (ja) | 2020-04-15 |
US20190002440A1 (en) | 2019-01-03 |
EP3395813A1 (en) | 2018-10-31 |
US10633368B2 (en) | 2020-04-28 |
ES2822081T3 (es) | 2021-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017108010A1 (zh) | 一种伏立康唑中间体及伏立康唑的合成方法 | |
JP2016516696A5 (zh) | ||
AU2011281421A1 (en) | Process for preparing aminobenzoylbenzofuran derivatives | |
TW201912656A (zh) | 舒更葡糖鈉之製備方法及其晶型 | |
CN110446704B (zh) | 用于制备磺酰胺结构化的激酶抑制剂的方法 | |
CN113816927A (zh) | 一种arv-471中间体的制备方法 | |
CN105348220A (zh) | 一种氢溴酸沃替西汀的合成方法 | |
CN105622595A (zh) | 一种阿奇沙坦酯钾盐及其中间体新的制备方法 | |
WO2021088296A1 (zh) | 一种新型4-硫氰基-1,4,5-三取代的1,2,3-三唑的制备方法 | |
CN109593083B (zh) | 一种苯醚甲环唑硝酸盐的制备方法 | |
CA3115742C (en) | Preparation method for efinaconazole | |
KR100990046B1 (ko) | 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법 | |
CN111718295B (zh) | 一种高纯度米力农的制备方法 | |
WO2014096018A1 (en) | Methods for the preparation of substituted acetophenones | |
CN111718292B (zh) | 一种米力农中间体化合物 | |
US20020115707A1 (en) | Process for preparing pure ondansetron hydrochloride dihydrate | |
CN113651762B (zh) | 一种1-甲基-1h-1,2,4-三氮唑-3-甲酸甲酯的制备方法 | |
EP2540717B1 (en) | Lamivudine oxalate and preparation method thereof | |
KR20150075187A (ko) | 텔미사르탄의 신규 제조 방법 | |
CN109071438B (zh) | 用于制备非索非那定和其中使用的中间体的方法 | |
CN117777109A (zh) | 伏立康唑及其中间体的制备方法 | |
EP2989099A1 (en) | A process for the synthesis of maraviroc | |
TW202328131A (zh) | 一種色烯—4—酮化合物及其中間體的製備方法 | |
EP2691387B1 (en) | Process for the preparation of anhydrous aripiprazole crystal form ii | |
WO2021120064A1 (zh) | 乙氧基亚甲基丙二腈的连续合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17732011 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018532219 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017732011 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017732011 Country of ref document: EP Effective date: 20180723 |